



Press release from Emotra AB (publ)  
Göteborg, January 23, 2014

## Emotra signs agreements with the universities of Bari and Piemonte

**Emotra has signed new agreements with a psychiatric clinic of the University of Piemonte in Novara and a psychiatric clinic at the University of Bari. These are the sixth and seventh clinics to sign agreements to participate in Emotra's clinical multi-centre study for the purpose of evaluating the use of EDOR to assess potential suicide risks.**

*"Through the new agreements with Novara and Bari, four Italian clinics have now signed agreements to participate in our multi-centre study. On January 17 we signed an agreement with the University of Genoa, and earlier today we signed an agreement with the University of Rome. We are engaged in far-reaching discussions with other clinics in Europe and are now trying to reach agreements with them," states Claes Holmberg, CEO of Emotra AB.*

So far, seven clinics have signed co-operation agreements with Emotra. Emotra plans to involve 15 leading European clinics in the evaluation of the method over the next two years, and discussions and negotiations are ongoing with several clinics from different countries. For the purpose of preparing these clinical studies, applications to ethical committees as well as for CE certification are simultaneously being drafted.

At present, Emotra is in the middle of a very dynamic phase involving an increasing number of clinical centres. In order to minimise the financial risks, all work is carried out within a small organisation and as cost-effectively as possible. When international, scientific support for EDOR from these clinics has grown sufficiently strong, we will launch the method in Europe.

**For further information, please contact:**

*Claes Holmberg, CEO*

*Telephone: +46 708 25 45 47*

*E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

*Lars-Håkan Thorell, Head of Research*

*Telephone: +46 733 95 31 20*

*E-mail: [lars@emotra.se](mailto:lars@emotra.se)*

---

**Emotra AB** is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. *Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.*